Cellular Immunotherapies: Late Phase and Commercially Available Therapies Impact of Salvage and Bridging Therapy in Adult Patients with Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL) Referred for Anti-CD19 CAR T-Cell Therapy: An Intention to Treat Analysis

被引：0

作者：

Ortiz-Maldonado, Valentin ^{[1
]}

Martinez-Cibrian, Nuria ^{[2
]}

Del Campo Balguerias, Gonzalo ^{[3
]}

Espanol-Rego, Marta ^{[4
]}

Navarro, Sergio ^{[4
]}

Brillembourg, Helena ^{[5
]}

Alserawan, Leticia ^{[4
]}

Castella, Maria ^{[4
]}

Benitez-Ribas, Daniel ^{[4
]}

Magnano, Laura ^{[5
]}

Gonzalo Correa, Juan ^{[5
]}

Rivero, Andrea ^{[5
]}

Mozas, Pablo ^{[5
]}

Oliver-Caldes, Aina ^{[6
]}

Gine, Eva ^{[7
]}

Gerardo Rodriguez-Lobato, Luis ^{[5
]}

Martinez-Roca, Alexandra ^{[2
]}

Montoro-Lorite, Mercedes ^{[5
]}

Ayora, Pilar ^{[5
]}

Fernandez de larrea, Carlos ^{[5
]}

Pascal, Mariona ^{[4
]}

Esteve Reyner, Jordi ^{[5
]}

Urbano-Ispizua, Alvaro ^{[5
]}

Juan, Manel ^{[8
]}

Delgado, Julio ^{[2
]}

机构：

[1] Hosp Clin Barcelona, Barcelona, Spain

[2] Hosp Clin Barcelona, Barcelona, Spain

[3] Hosp Clin San Carlos, Dept Hematol, Madrid, Spain

[4] Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain

[5] Hosp Clin Barcelona, Dept Hematol, Barcelona, Spain

[6] Univ Barcelona, Dept Hematol, Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[7] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Barcelona, Spain

[8] Hosp Clin Barcelona, Dept Immunol, Platform Immunotherapy Clin St Joan Deu, Barcelona, Spain

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187226

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

705

引用

页数：4

共 50 条

[1] Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation
Shang, Qianwen
Xue, Lian
Lu, Aidong
Jia, Yueping
Zuo, YingXi
Zeng, Huimin
Zhang, Leping
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (06): : 392 - 399.e5
[2] Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in B-cell acute lymphoblastic leukemia
Wang, Xiangmin
Zhang, Bingpei
Zhang, Qing
Zhou, Hongyuan
Sun, Qian
Zhou, Yi
Li, Tianci
Zhou, Dian
Shen, Ziyuan
Zhang, Jiaoli
Li, Ping
Liang, Aibin
Zhou, Keshu
Han, Lu
Hu, Yongxian
Yang, Yun
Cao, Jiang
Li, Zhenyu
Xu, Kailin
Sang, Wei
CANCER, 2024, 130 (15) : 2660 - 2669
[3] Anti-CD19 CAR T-cell therapy post antibody treatment in adult patients with relapsed/refractory precursor B-acute lymphoblastic leukemia
Danylesko, Ivetta
Besser, Michal
Jacoby, Elad
Itzhaki, Orit
Shem-Tov, Noga
Yerushalmi, Ronit
Toren, Amos
Shimoni, Avichai
Nagler, Arnon
Avigdor, Abraham
BONE MARROW TRANSPLANTATION, 2019, 54 : 517 - 518
[4] Anti-CD19/CD22 Dual CAR-T Therapy for Refractory and Relapsed B-Cell Acute Lymphoblastic Leukemia
Yang, Junfang
Jiang, Pengfei
Zhang, Xian
Zhu, Xiaobin
Dong, Qi
He, Jiaping
Lin, Nanjing
Wang, Zhenguang
Cai, Songbai
Ye, Xun
Su, Yunchao
Li, Wenqian
Li, Jingjing
Yu, Ziyao
He, Jiujiang
Xu, Li
Song, Dan
Cao, Wei
Lu, Peihua
BLOOD, 2019, 134
[5] SALVAGE THERAPIES AND OUTCOMES OF PATIENTS WITH RELAPSE OF B-ALL AFTER CD19 CAR T-CELL THERAPY
Friedes, Barbara
DiNofia, Amanda
Li, Yimei
Iannone, Emma
Rheingold, Susan
Leahy, Allison Barz
Wray, Lisa
Callahan, Colleen
Baniewicz, Diane
Liu, Hongyan
Getz, Kelly
Aplenc, Richard
Maude, Shannon
Grupp, Stephan
Myers, Regina
PEDIATRIC BLOOD & CANCER, 2023, 70 : S54 - S54
[6] Treatment of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy
Fang Liu
Sha Sha
Gina Ma
Yi Su
Yisong Xiong
Guangcui He
Yecheng Li
William M. Hanes
William Tse
Stem Cell Reviews and Reports, 2020, 16 : 1356 - 1358
[7] Treatment of CML-transformed B Cell Acute Lymphoblastic Leukemia (B-ALL) in Adults with Anti-CD19 Chimeric Antigen Receptor T Cell (CAR T) Therapy
Liu, Fang
Sha, Sha
Ma, Gina
Su, Yi
Xiong, Yisong
He, Guangcui
Li, Yecheng
Hanes, William M.
Tse, William
STEM CELL REVIEWS AND REPORTS, 2020, 16 (06) : 1356 - 1358
[8] Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Zhang, Xian
Lu, Xin-an
Yang, Junfang
Zhang, Gailing
Li, Jingjing
Song, Lisong
Su, Yunchao
Shi, Yanze
Zhang, Min
He, Jiujiang
Song, Dan
Lv, Fanyong
Li, Wenqian
Wu, Yan
Wang, Hui
Liu, Hongxing
Zhou, Xiaosu
He, Ting
Lu, Peihua
BLOOD ADVANCES, 2020, 4 (10) : 2325 - 2338
[9] Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL)
Topp, M. S.
Shah, B. D.
Ghobadi, A.
Oluwole, O. O.
Logan, A. C.
Boissel, N.
Cassaday, R. D.
Forcade, E.
Bishop, M. R.
Tzachanis, D.
O'Dwyer, K. M.
Arellano, M. L.
Lin, Y.
Baer, M. R.
Schiller, G. J.
Dong, J.
Shen, T.
Milletti, F.
Masouleh, Kharabi B.
Houot, R.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 16 - 16
[10] Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies
Yang, Xingcheng
Wei, Jia
Zhou, Jianfeng
HEMATOLOGICAL ONCOLOGY, 2022, 40 (05) : 821 - 834

← 1 2 3 4 5 →